Palisade Bio, Inc. (PALI) Earnings History
Annual and quarterly earnings data from 2005 to 2025
Loading earnings history...
PALI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PALI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | 100.0% | -5228.0% | -4920.0% |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export PALI earnings history in CSV or JSON format
Free sign-in required to download data
Palisade Bio, Inc. (PALI) Earnings Overview
As of May 8, 2026, Palisade Bio, Inc. (PALI) reported trailing twelve-month net income of -$17M, reflecting +97.1% year-over-year growth. The company earned $-0.30 per diluted share over the past four quarters.
Looking at the long-term picture, PALI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2005.
Palisade Bio, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$164M net income, -297.1% margin), HALO ($317M net income, 22.7% margin), CHRS ($168M net income, 398.4% margin), PALI has comparable earnings metrics. Compare PALI vs NKTR →
PALI Earnings vs Peers
Earnings metrics vs comparable public companies
PALI Historical Earnings Data (2005–2025)
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$17M | -16.2% | -$18M | $-0.30 | - | - |
| 2024 | -$14M | -17.4% | -$15M | $-10.19 | - | - |
| 2023 | -$12M | +13.7% | -$13M | $-27.01 | -4920.0% | -5228.0% |
| 2022 | -$14M | +46.4% | -$16M | $-16.53 | - | - |
| 2021 | -$27M | -157.9% | -$42M | $-2546.10 | - | - |
| 2020 | -$10M | -23.6% | -$9M | $-186.00 | - | - |
| 2019 | -$8M | -69.6% | -$9M | $-35.18 | -54254.9% | -56073.8% |
| 2018 | -$5M | +68.6% | -$8M | $-18.02 | -1894.2% | -3176.5% |
| 2017 | -$16M | +25.7% | -$13M | $-71.34 | -6025.4% | -5082.7% |
| 2016 | -$21M | -0.8% | -$20M | $-126.11 | -129724.2% | -124135.2% |
See PALI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PALI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PALI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPALI — Frequently Asked Questions
Quick answers to the most common questions about buying PALI stock.
Is PALI growing earnings?
PALI EPS is $-0.30, with earnings growth accelerating to +97.1%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-17M.
What are PALI's profit margins?
Palisade Bio, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are PALI's earnings?
PALI earnings data spans 2005-2025. The accelerating earnings trend is +97.1% YoY. Historical data enables comparison across business cycles.